Christopher Cooper

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

Anthony G Marson, Girvan Burnside, Richard Appleton et al. · The Lancet · 2021 · 211 citations · Full text

Medicine, Neurology, Pharmacology +17

The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

Anthony G Marson, Girvan Burnside, Richard Appleton et al. · The Lancet · 2021 · 191 citations · Full text

Medicine, Neurology, Pharmacotherapy +15

Effect of a collaborative weaning plan on patient outcome in the critical care setting

Elizabeth A. Henneman, Kathleen Dracup, Tomas Ganz et al. · Critical Care Medicine · 2001 · 67 citations

Health Professions, Health Care Management, Continuity Of Care +16

Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients

Gary E. Stein, Curtis Smith, Amy Scharmen et al. · Surgical Infections · 2018 · 52 citations

Medicine, Pharmacokinetics, Pharmacology +16

Use of healthcare claims to validate the Prevention of Arrhythmia Device Infection Trial cardiac implantable electronic device infection risk score

Fozia Ahmed, Carina Blomström‐Lundqvist, Heather L. Bloom et al. · EP Europace · 2021 · 35 citations · Full text

Medicine, Cardiology, Infection Prevention +14